Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Opdivo | Nivolumab | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adcetris (Resubmission) | Brentuximab Vedotin | Hodgkin lymphoma (HL) | Do not reimburse | Complete | ||
| Blincyto | Blinatumomab | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | Nonsquamous NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cabometyx | Cabozantinib | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vizimpro | Dacomitinib | Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imfinzi | Durvalumab | Unresectable Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xtandi | Enzalutamide | Non-metastatic castration-resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xermelo | telotristat | carcinoid syndrome | Do not reimburse | Complete |
Last Updated : April 29, 2024